1351237-65-4

Upstream product

• 615-09-8 ethyl 3-(2-furyl)-3-oxopropanoate 
• 1351238-42-0 7-amino-2-(furan-2-yl)thieno[2,3-b]pyrazine-6-carboxylic acid 
• 1351238-05-5 N-(3-amino-4-methylphenyl)-3-(2-cyanopropan-2-yl)benzamide hydrochloride 
• 1351238-41-9 ethyl 7-amino-2-(furan-2-yl)thieno[2,3-b]pyrazine-6-carboxylate 
• 1351238-40-8 3-bromo-6-(furan-2-yl)pyrazine-2-carbonitrile 
• 120930-05-4 3-amino-6-(furan-2-yl)pyrazine-2-carbonitrile 
• 120930-04-3 2-amino-3-cyano-5-(furan-2-yl)pyrazine 1-oxide 
• 67867-33-8 (E)-2-(furan-2-yl)-2-oxoacetaldehyde oxime 
• 872090-71-6 N-(3-amino-4-methylphenyl)-3-(2-cyanopropan-2-yl)benzamide 
• 872091-00-4 3-(1-cyano-1-methylethyl)benzoic acid 
• 872091-89-9 3-(2-cyanopropan-2-yl)-N-(4-methyl-3-nitrophenyl)benzamide 
• 872091-85-5 methyl 3-(1-cyano-1-methylethyl)benzoate 

Relevant academic research and scientific papers

THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS

The invention relates to compounds according to general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of cancer.

THIENO (2, 3B) PYRAZINE COMPOUNDS AS B - RAF INHIBITORS

The invention relates to compounds according to general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of cancer.